Skip to Content


Cell Therapy Using Monocytes and Macrophages

Updated on Mar 27, 2024 By Dominique Badea, PhD

3D Image of white blood cell monocyte

In the scientific discourse around adoptive cell immunotherapy, monocytes and macrophages often take a back seat. For the last two decades, immense time and resources have been spent developing T cell-based cancer therapeutics, such as T cell receptor (TCR) and chimeric antigen receptor (CAR) T therapy. For good reason, these therapies have proven incredibly successful in clinical trials for refractory blood cancers and lymphomas that failed other treatment attempts. Remembering …

How CAR Construct Transduction Impacts CAR T Therapy

Published on Mar 25, 2024 By Dominique Badea, PhD

Scientist wearing a lab coat, looking under microscope while using laptop in a laboratory

Cancer is a major challenge for the medical community, and it requires innovative and targeted treatment strategies to combat its various forms. One of the most promising strategies is CAR T cell therapy, a type of adoptive cell therapy that has demonstrated positive results, especially in treating hematologic malignancies such as leukemia. This immunotherapy leverages the power of the donor’s immune system, specifically T lymphocytes, which are genetically modified to …

CAR Constructs and the Impact of CAR T Cancer Therapy

Updated on Mar 1, 2024 By Jason Ellis, PhD

Cancer continues to pose significant health challenges worldwide, affecting millions of patients each year. Its diverse forms and complexity often require a multifaceted treatment approach. Over the years, various therapeutic strategies have emerged, each bringing its own set of benefits and challenges. Among these strategies, adoptive cell therapy stands out as a promising approach. It involves the direct infusion of immune cells—primed and empowered to combat malignancies—back into the patient. …

What Is Clinical GMP?

Updated on Feb 20, 2024 By Jason Ellis, PhD

Female Scientist Working in a Lab, Using the Computer

Good manufacturing practices (GMP)—are system that ensures products are consistently produced according to quality standards—is a concept most in the biotech industry are familiar with. But what exactly is clinical GMP? Clinical GMP specifically refers to the guidelines associated with products intended for human medical use. Unlike general GMP, which can pertain to various industries, clinical GMP focuses specifically on products intended for human consumption or application, ensuring that medical/medicinal …

Formula for Success: Preparing CAR T Cells for Infusion

Updated on Mar 1, 2024 By Jason Ellis, PhD

Scientists in a Lab Looking at Data on a Computer

As modern medicine continues to advance, the battle against cancer is increasingly being fought on a cellular level—and CAR T cell therapy is at the vanguard. Chimeric antigen receptor (CAR) T therapy is a remarkable form of immunotherapy that harnesses the body’s cellular defenses. It has revolutionized the treatment of malignancies such as lymphoma and blood cancers. Yet, the success of this therapy relies on more than just the genetically …

Approved CAR T Cell Therapies Revolutionize Cancer Treatment

Updated on Mar 1, 2024 By Jason Ellis, PhD

Hands Holding Colorful Cancer Awareness Ribbons

The emergence of CAR T cell therapies is one of the most promising developments in cancer treatment. This revolutionary approach, which involves reprogramming a patient’s own immune cells to fight cancer, has garnered significant attention and hope in the medical community. The recent approvals of adoptive cell therapies mark a new era in oncology and our understanding of the immune system, offering fresh avenues for patients battling various forms of …

What Is a CDMO?

Updated on Nov 17, 2023 By Jason Ellis, PhD

Two Technicians Analyzing Data on a Computer

A contract development and manufacturing organization (CDMO) is a business that provides drug development and manufacturing services to support product research, idea development, and production. New companies entering the medical or biotechnology space will face many regulatory hurdles before new products are ready for launch; and larger, more long-standing companies sometimes need additional manufacturing bandwidth. CDMOs manage multiple aspects of the product development process and guide companies through regulatory requirements …

The Power of T Cell Clonal Expansion

Published on Oct 30, 2023 By Jason Ellis, PhD

T-Cell Attacking a Cancer Cell

Clonal expansion is the process of rapid cell division resulting in the multiplication of genetically identical cell clones from a single parent cell. This exponential growth provides a robust concentration of specific genetic material that aids immune and developmental processes. Clonal expansion replaces damaged or worn tissues and old cells with new ones, healing wounds and aiding growth. In very early embryonic stages, cell expansion provides a rapid supply of …

What Is a Contract Research Organization?

Published on Oct 5, 2023 By Jason Xu, PhD

Two Scientists in Lab Coats Looking at a Computer Screen

Numerous discovery, development, and research stages exist before a new drug, pharmaceutical treatment, or medical device hits the market. Each of these stages brings unique challenges, and success depends heavily on the resources available to the sponsor of the novel treatment. Contract research organizations (CROs) provide specialized research, such as preclinical research, clinical trials, and a range of other research-based offerings, for biotechnology, pharmaceutical, and medical device companies on a …

Understanding GMP Leukopaks

Updated on Oct 5, 2023 By Dominique Badea, PhD

Two scientists conducting an experiment while wearing protective gear.

Leukopaks are an essential tool across medical and research applications, providing a robust source of white blood cells in a much higher concentration than whole blood samples. A leukopak is an enriched apheresis product collected via leukapheresis. During the leukapheresis process, white blood cells are collected and enriched by the simultaneous return of non-target blood cells to circulation. They contain a high concentration of peripheral blood mononuclear cells (PBMCs). As …

Back to Top